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Summary
Epigenetic modifications play an important role in hu-
man cancer. One such modification, histone methyla-
tion, contributes to human cancer through deregula-
tion of cancer-relevant genes. The yeast Dot1 and its
human counterpart, hDOT1L, methylate lysine 79 lo-
cated within the globular domain of histone H3. Here
we report that hDOT1L interacts with AF10, an MLL
(mixed lineage leukemia) fusion partner involved in
acute myeloid leukemia, through the OM-LZ region of
AF10 required for MLL-AF10-mediated leukemogene-
sis. We demonstrate that direct fusion of hDOT1L to
MLL results in leukemic transformation in an hDOT1L
methyltransferase activity-dependent manner. Trans-
formation by MLL-hDOT1L and MLL-AF10 results in
upregulation of a number of leukemia-relevant genes,
such as Hoxa9, concomitant with hypermethylation of
H3-K79. Our studies thus establish that mistargeting
of hDOT1L to Hoxa9 plays an important role in MLL-
AF10-mediated leukemogenesis and suggests that
the enzymatic activity of hDOT1L may provide a po-
tential target for therapeutic intervention.
Introduction
Covalent modifications of histone tails play important
roles in regulating chromatin dynamics and gene ex-
pression (Strahl and Allis, 2000). Among the various
modifications, histone methylation has attracted great
attention due to its diverse functions, which include
transcriptional regulation (Lachner et al., 2003; Zhang
and Reinberg, 2001). Histone methylation occurs on
both lysine and arginine residues that are usually lo-
cated on the N-terminal tails of histones H3 and H4.
With the exception of yeast Dot1 (Ng et al., 2002; van
Leeuwen et al., 2002) and its human homolog hDOT1L
(Feng et al., 2002), all the histone lysine methyltransfer-
ases (HKMases) identified thus far contain an evolu-
tionarily conserved motif, the SET [S(uv)3-9, E(z), Trx]
domain. Many of the HKMases have been linked to
cancer (Schneider et al., 2002). For example, the H3-*Correspondence: yi_zhang@med.unc.edulysine 4 (H3-K4) methyltransferase MLL is frequently
translocated in leukemia (Ayton and Cleary, 2001; Milne
et al., 2002; Nakamura et al., 2002); the EZH2 compo-
nent of the H3-lysine 27 (H3-K27) methyltransferase,
the EED-EZH2 complex, is overexpressed in a variety
of cancers and its protein level may be directly linked
to the invasiveness of these cancers (Bracken et al.,
2003; Kleer et al., 2003; Varambally et al., 2002).
Chromosomal translocation is one of the major
causes of human cancer, particularly in acute leuke-
mias. The most common chromosome rearrangements
found in leukemia patients involve the mixed lineage
leukemia gene MLL (also called ALL or HRX) located
at 11q23 (Ayton and Cleary, 2001; Daser and Rabbitts,
2004). MLL is the human homolog of Drosophila Tritho-
rax (Trx), a protein involved in maintaining the “on” state
of homeotic box (Hox) gene expression during embry-
onic development. MLL contains a number of func-
tional motifs including the N-terminal AT hook DNA
binding motif and the C-terminal SET domain required
for its H3-K4 methyltransferase activity (Milne et al.,
2002; Nakamura et al., 2002). As a result of chromo-
some translocation, the MLL N terminus becomes
fused in frame to one of more than 30 partner proteins
(Ayton and Cleary, 2001; Daser and Rabbitts, 2004). Re-
gardless of whether the fusion partner is normally local-
ized to the cell nucleus or cytoplasm, the chimeras are
always nuclear (Dimartino and Cleary, 1999). Since the
DNA binding domain of MLL is retained in the fusion
proteins, the MLL target genes are usually differentially
regulated as a result of a gain of function that is associ-
ated with the fusion partner proteins. Hoxa9 has
emerged as one of the most relevant MLL target genes
in human acute myeloid leukemia (AML) since it is al-
ways upregulated in AML (Golub et al., 1999). Indeed,
the leukemogenic potential of Hoxa9 was directly dem-
onstrated by the development of AML in mice receiving
transplantation of bone marrow cells overexpressing
Hoxa9 (Kroon et al., 1998). Recent studies indicated
that both Hoxa9 and Hoxa7 are required for MLL fusion
proteins to transform myeloid progenitor cells (Ayton
and Cleary, 2003). However, the mechanism by which
different MLL fusion proteins upregulate Hoxa9 and
how higher levels of Hoxa9 lead to leukemia are not
known.
Using biochemical and genetic approaches, we and
others have previously demonstrated that lysine 79 of
histone H3, located in the globular domain, is methyl-
ated by a non-SET domain protein called yeast DOT1
and its human homolog hDOT1L (Feng et al., 2002; Ng
et al., 2002; van Leeuwen et al., 2002). Here we report
the identification of AF10, an MLL fusion partner in hu-
man leukemia, as an hDOT1L-interacting protein. The
interaction is mediated by an octapeptide motif and a
leucine zipper (OM-LZ) region of AF10 required for leu-
kemic transformation by MLL-AF10. Importantly, fusion
of hDOT1L to MLL is capable of leukemic transforma-
tion in an hDOT1L HMTase activity-dependent manner.
Moreover, an HMTase-defective hDOT1L mutant is ca-
pable of suppressing growth of MLL-AF10-transformed
Cell
168cells. Transformation of progenitor bone marrow cells T
Tby MLL-AF10 or MLL-hDOT1L results in upregulation of
fa set of leukemia-relevant Hox genes, including Hoxa9,
Aconcomitant with hypermethylation on H3-K79. Our
mstudy thus reveals a role for hDOT1L-mediated H3-K79
fmethylation of MLL target genes in leukemogenesis
aand raises the intriguing possibility that the HMTase ac-
otivity of hDOT1L can serve as a target for therapeutic
Mintervention of human leukemia.
s
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h
CIdentification of AF10, an MLL Fusion Protein
nin Leukemia, as an hDOT1L-Interacting Protein
iWe have previously cloned the human homolog of
syeast DOT1 and demonstrated its H3-K79-specific
tmethyltransferase activity (Feng et al., 2002). To under-
rstand the function of hDOT1L, we searched for its func-
ptional partners by yeast two-hybrid screening using
bhDOT1L as bait. This screen resulted in repeated isola-
ttion of cDNAs encoding the C-terminal half of AF10
s(data not shown), a frequent fusion partner of MLL and
sCALM in leukemia (Chaplin et al., 1995; Dreyling et al.,
l1996). To confirm the interaction, we coexpressed AF10
tand hDOT1L that were tagged with Flag and HA,
Orespectively. Following immunoprecipitation and West-
aern blot analysis, we demonstrated that the two pro-
F
teins can be coimmunoprecipitated (Figure 1A, com-
w
pare lanes 3 and 6).
l
To demonstrate an association of the two proteins
s
at endogenous protein levels, we raised a polyclonal p
antibody against hDOT1L. While this antibody can A
recognize as little as 2 ng of recombinant hDOT1L p
in Western blotting, it failed to detect endogenous O
hDOT1L in a number of cell sources (data not shown). b
In an effort to identify a cell source for detection of the h
endogenous hDOT1L protein, both Northern blotting
and microarray analysis were performed. Results indi- t
cated that both human and mouse DOT1L genes are h
broadly expressed (Figure S1) (Zhang et al., 2004). In- i
terestingly, hematopoietic stem cells and some leuke- h
mia/lymphoma cell lines exhibit relatively higher ex- a
pression levels (Figure S1B). Due to its relatively higher d
level of hDOT1L expression, Raji cells were used for g
nuclear extract preparation and coimmunoprecipitation g
experiments. Results shown in Figure 1B demonstrate T
that the antibody against AF10 not only immunoprecipi- t
tated itself but also coimmunoprecipitated hDOT1L t
(lane 6). The immunoprecipitation is specific, as a paral- L
lel immunoprecipitation using equal amounts of mouse o
IgG failed to immunoprecipitate either protein (lane 3). b
In addition, we also attempted to coimmunoprecipitate r
AF10 using the hDOT1L antibody. However, hDOT1L b
protein can only be immunoprecipitated under denatur-
ing conditions (Figure S2), indicating that either the T
hDOT1L epitopes or the entire protein is inaccessible b
by the hDOT1L antibody under native conditions. The A
above results, in combination with the mammalian two- T
hybrid results shown below, allow us to conclude that p
TAF10 and hDOT1L associate in vivo.he OM-LZ Region of AF10, Required for Leukemic
ransformation, Is Both Necessary and Sufficient
or AF10-hDOT1L Interaction
F10 was initially discovered by virtue of its involve-
ent in t(10;11)(p12;q23) chromosomal translocations
ound in acute myeloid leukemia patients (Chaplin et
l., 1995). The genetic rearrangement results in fusion
f the C-terminal half of AF10 to the N-terminal third of
LL. AF10 contains several motifs common to tran-
cription factors, and the minimal portion of AF10 that
s leukemogenic when fused to MLL contains a leucine
ipper (LZ) motif and an octapeptide motif (OM) that is
ighly conserved between homologs of AF10 from
. elegans to human (Figure 1C). To characterize the
ature of the AF10-hDOT1L interaction, we mapped the
nteraction region using a mammalian two-hybrid as-
ay. AF10 and hDOT1L that were fused to the VP16 ac-
ivation domain and the Gal4-DNA binding domain,
espectively, were coexpressed in 293T cells in the
resence of a luciferase reporter containing five Gal4
inding sites. Results shown in Figure 1D demonstrate
hat the 80 amino acid (aa 719–800) OM-LZ region is
ufficient to mediate the interaction. Interestingly, this
ame region was previously reported to be required for
eukemic transformation by the MLL-AF10 fusion pro-
ein (DiMartino et al., 2002). To evaluate whether the
M-LZ region is necessary for the interaction, we cre-
ted an AF10 construct where this region was deleted.
lag-AF10 with or without this region was coexpressed
ith hDOT1L- HA and their ability to interact was ana-
yzed by coimmunoprecipitation. Although both con-
tructs expressed at a similar level (Figure 1E, left
anel), deletion of the OM-LZ region abrogated the
F10-hDOT1L interaction (Figure 1E, right panel, com-
are lanes 6 and 9). Therefore, we conclude that the
M-LZ region on AF10 required for leukemogenesis is
oth necessary and sufficient in mediating the AF10-
DOT1L interaction.
To evaluate the relative contribution of OM and LZ
o the AF10-hDOT1L interaction, we created constructs
arboring mutations in the two regions individually or
n combination and analyzed their effect on the AF10-
DOT1L interaction using the mammalian two-hybrid
ssay described above. Results shown in Figure 1F in-
icate that while mutation in each of the two regions
reatly reduced their interaction, mutations in both re-
ions together completely abrogated the interaction.
hus, we conclude that both OM and LZ contribute to
he hDOT1L-AF10 interaction. This result, in combina-
ion with the previous demonstration that both OM and
Z contribute to the leukemic transformation capability
f MLL-AF10 (DiMartino et al., 2002),raise the possi-
ility that recruitment of hDOT1L by MLL-AF10 may di-
ectly contribute to the leukemic transformation capa-
ility of MLL-AF10.
ransformation of Murine Myeloid Progenitor Cells
y MLL-hDOT1L Requires the HMTase
ctivity of hDOT1L
he above results suggest that hDOT1L may partici-
ate in MLL-AF10-mediated leukemic transformation.
o determine whether MLL-AF10 is capable of recruit-
hDOT1L and Leukemia
169Figure 1. The OM-LZ Region of AF10, Required for Leukemogenesis of MLL-AF10, Is Both Necessary and Sufficient for hDOT1L and AF10 In-
teraction
(A) AF10 and hDOT1L coimmunoprecipitate when coexpressed in 293T cells. Flag and HA antibodies were used for immunoprecipitation and
Western blotting, respectively.
(B) Coimmunoprecipitation of endogenous hDOT1L and AF10. To stabilize hDOT1L protein, Raji cells were treated with 10 M MG-132
(Peptides International) for 10 hr before harvesting. An anti-AF10 monoclonal antibody was used for immunoprecipitation. The same amount
of mouse IgG was used as a control. Antibodies used for Western blotting are indicated. In, FT, and IP represent input (3%), flow-through,
and bound, respectively.
(C) Diagram of AF10 functional motifs and sequence alignment of the OM-LZ region. Arrow indicates the break point for MLL-AF10 fusion.
Human AF10 (GenBank number AAT47519) and its homologs from mouse (GenBank number O54826), Drosophila (GenBank number
AAF72595), and C. elegans (GenBank number 2122400A) were compared. Conserved amino acids are marked in red. Mutations on the amino
acids marked by * affect the interaction between hDOT1L and AF10 (E).
(D) Mammalian two-hybrid analysis located the OM-LZ region of AF10 to be sufficient for mediating AF10 and hDOT1L interaction. The bars
represent average fold of activation from four independent experiments.
(E) Coimmunoprecipitation experiments demonstrating that the OM-LZ region of AF10 is necessary for the AF10 and hDOT1L interaction.
Western blotting shown on the left panel indicates that the wild-type and the deletion mutant proteins were expressed to a similar level.
(F) Mammalian two-hybrid assays demonstrating that both the evolutionarily conserved octapeptide (EQLLERQW) motif (OM) and the leucine
zipper (LZ) of AF10 contribute to the interaction. The mutations are marked by * as in (B). The bars represent average fold of activation from
four independent experiments.ing hDOT1L, we performed immunofluorescence and
coimmunoprecipitation studies. Consistent with the
ability of MLL-AF10 to interact with hDOT1L, immuno-
fluorescence staining revealed colocalization of trans-
fected hDOT1L and MLL-AF10 at large nuclear foci
(Figure 2A), similar to those observed for the endoge-
nous MLL protein (Caslini et al., 2000). In addition, the
interaction was also confirmed by coimmunoprecipita-
tion (data not shown). If the fused AF10 in MLL-AF10
only serve to recruit hDOT1L, leukemic transformation
may be achieved by direct fusion of hDOT1L to MLL.To test this possibility, we analyzed the ability of MLL-
hDOT1L to immortalize murine progenitor bone marrow
cells using a myeloid colony-formation assay outlined
in Figure 2B. Toward this end, a modified murine stem
cell virus (MSCV) derived retroviral vector, designated
as MSCN, was used to transduce freshly harvested
bone marrow progenitor cells from mice pretreated with
5-fluorouracil. MSCN constructs encoding MLL se-
quences 5# of the translocation breakpoint (MLL-N),
MLL-AF10 that mimics the most frequent fusion involv-
ing the two proteins, and MLL fused to various length
Cell
170Figure 2. The HMTase Activity of hDOT1L Is Required for Bone Marrow Transformation Capability of MLL-hDOT1L
(A) Immunofluorescence staining revealing colocalization of hDOT1L with MLL-AF10 to a few large foci when the two proteins are coex-
pressed.
(B) Schematic presentation of the retroviral transduction procedures.
(C) Diagram of retroviral constructs expressing MLL, MLL-AF10, and MLL-hDOT1L (left panel). The numbers refer to the amino acid number
of corresponding proteins. The HMTase-defective mutant contains a GSG to RCR mutation in the SAM binding domain (Feng et al., 2002).
Colony numbers generated in the first, second, and third round of plating of 1 × 104 transduced bone marrow cells are shown (right panel).
The various controls and fusion proteins transduced are indicated. Data presented are an average of Rfour independent experiments with
error bars.of hDOT1L were made (Figure 2C, left panel and data a
mnot shown). To facilitate monitoring expression of these
constructs, an N-terminal Flag-tag was added to each “
tof them. Due to the size limitation for efficient packag-
ing of retroviral vectors, MLL-hDOT1L fusion constructs f
cthat encode longer than the first 670 amino acids of
hDOT1L have dramatically decreased retroviral trans- h
sduction efficiency (data not shown). This prevented us
from analyzing MLL-hDOT1L that contains the full- d
tlength hDOT1L. Nevertheless, retroviruses with similar
titer as that of MLL-AF10 were successfully generated p
twith MLL-hDOT1L(1–670) (data not shown).
We have shown previously that the N-terminal 416 e
camino acids of hDOT1L have robust H3-K79 HMTase
activity in vitro (Min et al., 2003b). Importantly, HMTase rssays demonstrate that MLL-hDOT1L(1–670) is enzy-
atically active, while the protein harboring the
GSG163-165RCR” mutations is enzymatically inac-
ive (data not shown). Western blotting of extracts
rom transiently transfected retroviral packaging cells
onfirmed that MLL-N, MLL-AF10, MLL-hDOT1L, and
DOT1L constructs were efficiently expressed (data not
hown). Plating of bone marrow progenitor cells trans-
uced with the various MSCN constructs under selec-
ive conditions showed a variable number (50–200) of
rimary or first round colonies that are consistent with
heir respective virus titer. However, significant differ-
nces were observed in a second round plating of 104
ells pooled from colonies harvested from the first
ound of cultures. Compared to the first round, vector
hDOT1L and Leukemia
171alone, MLL-N, hDOT1L, and the MLL-hDOT1L mutant
transduced cultures produced a decreased number of
colonies. In contrast, MLL-hDOT1L- and MLL-AF10-
transduced cells gave rise to hundreds if not thousands
of colonies, an amount significantly higher than that
from the first round of plating (Figure 2C, right panel).
When a third round of plating was assayed, only MLL-
hDOT1L- and MLL-AF10-transduced cells gave rise to
increased number of colonies compared with that from
the second round of plating (Figure 2C, right panel).
These results allow us to conclude that similar to MLL-
AF10, MLL-hDOT1L has leukemic transformation capa-
bility and the ability depends on the HMTase activity
of hDOT1L.
hDOT1L HMTase Activity Is Required for
Maintenance of the Transformed Cell Status
in Cells Transformed by MLL-AF10
Having established a role for the HMTase activity of
hDOT1L in transforming murine primary bone marrow
progenitor cells, we asked whether the HMTase activity
is also required for maintaining the MLL-AF10-trans-
formed cell status. To address this question, we exam-
ined the effect of the wild-type hDOT1L and the
HMTase-defective mutant hDOT1L on the sustaining
growth capability of MLL-AF10-transformed bone mar-
row cells. Full-length wild-type and HMTase-defective
mutant hDOT1L were cloned into retroviral vectors ex-
pressing the Blasticidin resistance gene. Viruses gener-
ated were used to infect MLL-AF10-transduced/trans-
formed bone marrow cells derived from second round
plating (Figure 3A). Cells expressing hDOT1L were se-
lected in the presence of Blasticidin. After 10 days of
methylcellulose culture, we noticed a dramatic differ-
ence in the colony-formation assay (Figure 3B). While
transduction of wild-type hDOT1L to MLL-AF10-
expressing cells does not significantly alter the colony-
formation capability when compared with transduction
of an empty vector, transduction of HMTase-defective
hDOT1L to MLL-AF10 significantly suppressed the abil-
ity of MLL-AF10 to support colony formation.
The above results have two possible explanations.
The first is that the mutant hDOT1L may have a general
role in suppression of cell growth. Alternatively, the mu-
tant hDOT1L may function in a dominant-negative fash-
ion by preventing recruitment of wild-type hDOT1L to
MLL-AF10 target genes such as Hoxa9 whose expres-
sion is required for maintaining the transformed cell
status (Ayton and Cleary, 2003). To differentiate be-
tween these two possibilities, we repeated the above
experiments using MLL-AFX-transformed cells. MLL-
AFX was chosen because the long latency, reduced
penetrance, and hematologic features of the leukemias
induced by this fusion protein are in contrast with the
more aggressive features of leukemias induced by
MLL-AF10 (So and Cleary, 2003), and consequently the
two fusion proteins are likely to employ different mech-
anisms of leukemogenesis. In contrast with the effect
observed on MLL-AF10-transformed cells, no signifi-
cant effect on MLL-AFX-transformed cells was ob-
served when wild-type or mutant hDOT1L were ex-
pressed (Figure 3B). These results indicate that the
dominant-negative effect observed on MLL-AF10-trans-formed cells is specific and consistent with a role for
the HMTase activity of hDOT1L in maintaining the
growth capability of murine bone marrow cells trans-
formed by MLL-AF10.
siRNA-Mediated mDOT1L Knockdown
Impairs Cell Proliferation
The above results indicate that hDOT1L is critical in
MLL-AF10-mediated leukemic transformation. To gain
further supporting evidence for this conclusion, we at-
tempted to attenuate the mouse DOT1L (mDOT1L)
function in progenitor bone marrow cells using siRNA-
mediated knockdown and asked whether the cells can
still be transformed by MLL-AF10. To this end, two
siRNA retroviral constructs that target different regions
of the mDOT1L mRNA were made and their ability in
knocking down mDOT1L in 3T3 cells was confirmed by
RT-PCR (Figure S3A). As outlined in Figure 3C, progeni-
tor bone marrow cells were transduced with the knock-
down viruses. After selection under Blasticidin, the
recovered colonies were analyzed for mDOT1L expres-
sion and for transduction by MLL-AF10 as well as MLL-
AFX. Although knockdown viruses that express RNAi2
are more efficient in knocking down mDOT1L in 3T3
cells (Figure S3A), transduction of progenitor bone mar-
row cells with viruses expressing RNAi2 generated no
knockdown colonies. This is likely due to the require-
ment of a certain level of mDOT1L for cell survival (see
below). However, we were able to recover colonies from
transduction by the viruses expressing RNAi1, which
resulted in about 50% knockdown (Figure 3D and Fig-
ure S3A). Transduction of these recovered mDOT1L
knockdown cells by MLL-AF10, MLL-AFX, or vector
control generated no colonies (Figure 3E). In contrast,
large numbers of colonies were generated when the
mock vector knockdown cells were transduced by the
same MLL-AF10-, MLL-AFX-expressing viruses in par-
allel experiments (Figure 3E). No colony was generated
from mDOT1L knockdown cells transduced by MLL-
AFX, even though the bone marrow transformation ca-
pability of MLL-AFX is not dependent on hDOT1L (Fig-
ure 3B). Given this fact, we believe that a critical level
of mDOT1L is required for cell survival. This interpreta-
tion is consistent with our observation in 3T3 cells
where both RNAi1 and 2 expression resulted in cell
growth arrest and cell death, and the more efficient
RNAi2 exhibited a more severe phenotype (Figures S3B
and S3C).
MLL-hDOT1L Immortalizes Murine
Myeloid Progenitors
The similar GM (granulocyte-macrophage)-like mor-
phology of the colonies formed fromMLL-hDOT1L- and
MLL-AF10-transduced bone marrow cells (Figure 4A)
suggested that MLL-hDOT1L-transformed cells, like
those transformed by MLL-AF10 (DiMartino et al.,
2002), were likely to be of myeloid lineage. To test this
possibility, we first verified that both MLL-hDOT1L and
MLL-AF10 were expressed in cells derived from the re-
spective colonies (Figure 4B). Then, cell lineages were
analyzed by Wright-Giemsa staining and FACS using
antibodies against specific cell-surface markers (Fig-
ures 4C–4F). Wright-Giemsa-stained cytospin prepara-
Cell
172Figure 3. Role of hDOT1L and Its HMTase Activity in Maintenance of Transformed State and Cell Survival
(A) Diagram of the transduction procedure.
(B) The HMTase-defective hDOT1L attenuates proliferation of MLL-AF10-transformed cells, but not that of MLL-AFX-transformed cells. To
adjust for the difference in titers of the different viruses, relative colony numbers were used (vector control was calculated as 100%). Data
presented are an average of four independent experiments with error bars.
(C) Diagram of the sequential transduction of bone marrow cells with mDOT1L RNAi followed by MLL-AF10/MLL-AFX.
(D) Quantification of the mDOT1L knockdown efficiency by RT-PCR. Numbers of PCR cycles were indicated. GAPDH was used as a control.
(E) Effect of mDOT1L knockdown on colony formation of MLL-AF10- or MLL-AFX-transduced bone marrow cells. Colony numbers are indi-
cated as an average of two independent experiments.tions revealed that colonies derived fromMLL-hDOT1L- p
Mtransduced cells have similar features as those derived
from MLL-AF10. The majority of the cells appear to be p
cimmature myeloblasts. However, a few differentiated
macrophage-like cells were also visible (Figure 4C). Im- m
omunophenotyping of the cells from the third round oflating revealed that almost all of the cells derived from
LL-AF10- or MLL-hDOT1L-transduced colonies ex-
ressed the early hematopoitic progenitor cell marker
-Kit and about half of them expressed the myeloid cell
arker CD11b but not Gr-1 (Figures 4D and 4E). None
f the cells expressed the B cell lineage marker B220
hDOT1L and Leukemia
173Figure 4. Bone Marrow Progenitor Cells
Transformed by MLL-hDOT1L Are of My-
eloid Lineage
(A) Morphology of colonies formed in the
third round of methylcellulose assays trans-
duced by MLL-hDOT1L (upper panel) and
MLL-AF10 (lower panel). Original magnifica-
tion ×5.
(B) RT-PCR detection of the expression of
the transduced genes in cells derived from
the colonies.
(C) Wright-Giemsa-stained cytospin prepa-
ration of cells from the third round of colo-
nies. Original magnification ×40.
(D–F) Immunophenotyping by FACS of cells
from the third round of colonies transduced
by MLL-hDOT1L and MLL-AF10. The cell-
surface markers used are indicated.or the T cell lineage marker CD3 (Figure 4F). In addition,
markers for mast cells (IgE) or erythrocytes (Ter119)
were also absent (data not shown). These results sug-
gest that although the colony numbers formed by MLL-
hDOT1L and MLL-AF10 transduction are not the same,
both are capable of immortalizing bone marrow pro-
genitor cells at a relatively early stage of myeloid differ-
entiation. Nevertheless, MLL-hDOT1L cannot com-
pletely phenocopy MLL-AF10 (see below). Whether the
difference is caused by the use of a partial, instead of
the full-length, hDOT1L in the MLL fusion or additional
factors are recruited by AF10 remains to be deter-
mined.
Hoxa9 and Hoxa7 Upregulation Is Associated
with Transformation
In addition to participating in embryogenesis, Hox
genes also play important roles in normal hematopoie-
sis and leukemogenesis (Buske and Humphries, 2000;
Sauvageau et al., 1994). To understand how hDOT1L
and its associated HMTase activity contribute to leuke-
mogenesis, we determined the expression profile of
Hoxa genes in vector-transduced and MLL-AF10- or
MLL-hDOT1L-transduced murine progenitor bone mar-
row cells. Toward this end, we analyzed the expression
levels of all 13 Hoxa genes by semiquantitative reverse
transcriptase PCR (RT-PCR). Similar to a previous re-
port (Ayton and Cleary, 2003), cells immortalized by
MLL-AF10 resulted in upregulation of a number of
genes in the Hoxa locus relative to that of vector-trans-
duced cells (Figure 5A). Consistent with the fact that
MLL-hDOT1L did not completely phenocopy MLL-AF10
in the transformation assay, cells derived from MLL-hDOT1L-transduced colonies had fewer numbers of
Hoxa genes upregulated relative to that from MLL-
AF10-transduced cells. However, Hoxa9, Hoxa7, and
Meis1 are upregulated in cells transformed by either
MLL-AF10 or MLL-hDOT1L, consistent with the fact
that these genes are required for MLL fusion protein-
mediated transformation (Ayton and Cleary, 2003). Sim-
ilar to a previous report about the upregulation of
Hoxa5 and Hoxa11 by MLL fusion proteins (Ayton and
Cleary, 2003), we also detected upregulation of these
two genes in MLL-hDOT1L-transduced cells. Whether
upregulation of either one or both is a requirement for
leukemic transformation remains to be determined.
Hoxa9 Is Required for MLL-AF10- and MLL-hDOT1L-
Mediated Bone Marrow Cell Immortalization
Previous studies have demonstrated that both Hoxa9
and Hoxa7 are independently required for immortaliza-
tion of bone marrow cells by MLL-ENL (Ayton and
Cleary, 2003). Given that both Hoxa9 and Hoxa7 are
upregulated in cells transformed by MLL-AF10 and
MLL-hDOT1L, we evaluated the requirement of Hoxa9
in progenitor bone marrow cell transformation by MLL-
AF10 or MLL-hDOT1L. Toward this end, progenitor
bone marrow cells isolated from Hoxa9−/− mice were
transduced by MLL-AF10 or MLL-hDOT1L and ana-
lyzed by the methylcellulose colony replating assay as
described in Figure 2B. Results shown in Figure 5B in-
dicate that the Hoxa9 gene is required for immortaliza-
tion of progenitor bone marrow cells by both MLL-AF10
and MLL-hDOT1L because neither MLL-AF10 nor MLL-
hDOT1L is capable of immortalizing Hoxa9-deficient
progenitor bone marrow cells.
Cell
174Figure 5. Expression of Hoxa9 Is Required for Transformation of Mouse Progenitor Bone Marrow Cells by MLL-AF10 and MLL-hDOT1L
(A) Upregulation of late Hoxa and Meis1 genes in cells transduced by MLL-AF10 and MLL-hDOT1L. Expression of Hoxa and Meis1 genes,
analyzed by RT-PCR, in MLL-AF10- and MLL-hDOT1L-transformed cells (second round colonies) was compared with that in cells infected
with an empty retrovirus vector (first round colonies). The expression of Meis1 was analyzed because Meis1 was reported to collaborate with
late Hoxa genes in myeloid leukemogenesis (Nakamura et al., 1996). GAPDH serves as a control for equal input in RT-PCR of different
samples. Template amounts and cycle numbers for PCR are described in Experimental Procedures.
(B) Hoxa9 knockout attenuates the transformation ability of MLL-AF10 and MLL-hDOT1L. Colony assays were performed as that in Figure 2.
Colony numbers generated in the first, second, and third round from plating 1 × 104 transduced bone marrow cells are shown. Data represents
average of three independent experiments with error bars.Hoxa9 Upregulation Correlates M
(with H3-K79 Hypermethylation
Having demonstrated the requirement for the Hoxa9
pgene in MLL-AF10- and MLL-hDOT1L-mediated leuke-
mic transformation, we attempted to determine the mo- i
alecular basis underlying Hoxa9 upregulation. Using my-
eloid progenitor cells immortalized by MLL-hDOT1L or w
cMLL-AF10, we first determined the location of the fu-
sion proteins on the Hoxa9 gene by ChIP analysis. M
aSince the fusion proteins were tagged by an N-terminal
Flag, a monoclonal antibody against Flag was used in i
tthe ChIP assay. As a negative control, a monoclonal
antibody against HA was used in parallel experiments. w
cDNA recovered from the ChIP experiments was ampli-
fied by PCR using 24 pairs of primers that cover the t
iregion from the last exon of Hoxa10 to the first exon of
Hoxa7 (Figure 6A). Results revealed a similar distribu- n
ition of the two fusion proteins with the exception of
two regions (amplicons o-p, v-x). The presence of MLL- r
MAF10, but not MLL-hDOT1L, in these two regions up-
stream of Hoxa7 is consistent with the fact that the 1
hHoxa7 expression level is higher in cells transformed byLL-AF10 relative to that transformed by MLL-hDOT1L
Figure 5A).
Having determined the localization of the MLL fusion
roteins, we analyzed the histone modification patterns
n the regions where both MLL-hDOT1L and MLL-AF10
re enriched (amplicons a, g, i, j, and s). Our analysis
as focused on H3-K79 and H3-K4 methylation be-
ause these two sites are targeted by the hDOT1L and
LL HMTases, respectively (Feng et al., 2002; Milne et
l., 2002; Nakamura et al., 2002). Consistent with bind-
ng of MLL to these sites in normal bone marrow cells
ransduced with an empty vector, H3-K4 methylation
as detected (Figure 6B, compare lanes 5 and 6). In
ontrast, no significant H3-K79 methylation was de-
ected at any of these sites (Figure 6B, lane 4), suggest-
ng that hDOT1L is not recruited to the Hoxa9 gene in
ormal bone marrow cells. Interestingly, similar analysis
n leukemic cells revealed robust H3-K79 methylation,
egardless of whether the cells were transformed by
LL-hDOT1L or MLL-AF10 (Figure 5B, lanes 10 and
6). With the exception of amplicon “a,” all showed
igher levels of H3-K79 methylation in MLL-AF10-trans-
hDOT1L and Leukemia
175Figure 6. Upregulation of Hoxa9 Expression
Correlates with Hypermethylation of H3-K79
on Hoxa9 Genes in Cells Transduced by
MLL-AF10 and MLL-hDOT1L
(A) Localization of MLL-hDOT1L and MLL-
AF10 binding regions at the Hoxa9 locus by
ChIP assays. The PCR amplicons (a–x) in re-
lation to the Hoxa9 gene structure are indi-
cated. Data presented depict the relative en-
richment of MLL-hDOT1L/MLL-AF10 across
the entire Hoxa9 gene locus.
(B) Comparison of the dimethylation levels
on H3-K4 and H3-K79 in cells transduced by
MLL-hDOT1L and MLL-AF10 with that trans-
duced by an empty retroviral vector. Pres-
ence of Flag-MLL-hDOT1L or Flag-MLL-
AF10 on different locations along the Hoxa9
gene was verified by ChIP using Flag anti-
body. IgG and HA antibodies serve as con-
trols. Only selected amplicons, indicated on
the left of the panel, were analyzed.formed cells when compared with that of cells trans-
formed by MLL-hDOT1L (compare lanes 10 and 16).
This could be explained in a number of ways. For exam-
ple, fusion of MLL to hDOT1L could inhibit hDOT1L
HMTase activity. Alternatively, the lack of an hDOT1L
C-terminal in the fusion protein could prevent recruit-
ment of cofactors required for optimal hDOT1L HMTase
activity. Comparison of the H3-K4 methylation levels in
normal and leukemic cells (Figure 6B, compare lanes
11 and 17 with lane 5) revealed a general decrease,
which is consistent with the fact that MLL-hDOT1L or
MLL-AF10 may compete with endogenous MLL for
binding to these sites. Collectively, the above results
support the notion that leukemogenesis by MLL-AF10
involves upregulation of Hoxa9 mediated through re-
cruitment of hDOT1L and subsequent H3-K79 methyla-
tion. How methylation on H3-K79 leads to transcription
activation remains to be determined.
Discussion
MLL belongs to the Trithorax group of proteins and is
involved in maintaining the “on” state of Hox gene ex-
pression. Recent studies indicate that one way in which
MLL maintains Hox gene expression might be through
methylation of H3-K4 at MLL binding sites (Milne et al.,
2002; Nakamura et al., 2002). Chromosome transloca-
tions involving MLL are associated with the majority of
myeloid leukemia in human patients (Ayton and Cleary,2001; Daser and Rabbitts, 2004). As a result of chromo-
some translocation, the N terminus of MLL becomes
fused in-frame to one of a wide variety of proteins. The
fusion proteins retain the DNA binding domain of MLL
and lose the C-terminal SET domain, thus the H3-K4
methyltransferase activity. At the same time, the fusion
proteins gain function that is associated with the part-
ner protein. Since the DNA binding domain of MLL is
retained in the translocation, MLL fusion proteins are
expected to target the same sets of genes as those
targeted by MLL. The fact that H3-K4 methylation is
linked to transcriptional activation (Santos-Rosa et al.,
2002), in combination with the fact that MLL fusion pro-
teins do not possess H3-K4 methyltransferase activity,
imply that MLL target genes may be downregulated in
leukemia involving MLL fusion. However, contrary to
this prediction, most of the leukemia-relevant MLL
target genes, such as the late HoxA genes, are upregu-
lated in MLL fusion protein-mediated leukemias (Ayton
and Cleary, 2003). To explain this seemingly contradic-
tory outcome, the effect on transcription caused by the
loss of the H3-K4 methyltransferase activity must be
overcome by the transcriptional activity gained from
the fusion partner. In this study, we provide several lines
of evidence suggesting that one way to compensate
for the loss of H3-K4 methyltrasferase activity is the
recruitment of hDOT1L, an H3-K79 HMTase previously
linked to transcriptional activation (Feng et al., 2002;
Ng et al., 2002; van Leeuwen et al., 2002).
Cell
176Figure 7. Models Illustrate the Involvement
of hDOT1L in Hoxa9 Regulation and Myeloid
Transformation by MLL-AF10
(A) During normal myeloid cell differentiation,
MLL complex induces methylation on H3-K4
and maintains the basal level of Hoxa9 ex-
pression.
(B) In myeloid cells with MLL-AF10 fusion,
hDOT1L is recruited to MLL target genes,
such as Hoxa9, through an interaction with
the OM-LZ of AF10, leading to hypermeth-
ylation of H3-K79 and upregulation of Hoxa9.
(C) The HMTase-defective hDOT1L mutant
can function in a dominant-negative fashion
to prevent recruitment of the wild-type
hDOT1L leading to inhibition of Hoxa9 ex-
pression and leukemogenesis. The thickness
of the arrows represents relative expression
levels.In searching for hDOT1L-interacting proteins, we o
iidentified AF10, a frequent fusion partner of MLL in leu-
kemia patients. The fact that the hDOT1L-AF10 interac- t
Htion is mediated through the OM-LZ domain of AF10
required for leukemogenesis raised the possibility that b
2AF10 may function as a bridge for the recruitment of
hDOT1L to the genes targeted by MLL-AF10 (Figure 1). m
uConsistent with this possibility, direct fusion of hDOT1L
to MLL resulted in transformation of bone marrow pro-
cgenitor cells. Importantly, both the cell lineage (Figure
4) and Hoxa gene expression pattern (Figure 5A) of the a
atransformed cells are similar to those transformed by
MLL-AF10, supporting the possibility that one of the e
rmajor function of AF10 in MLL-AF10 is to recruit
hDOT1L. In addition, our study indicates that the trans- a
(formation ability of MLL-hDOT1L is dependent on the
H3-K79 methyltransferase activity of hDOT1L (Figure i
(2C). Furthermore, overexpression of an HMTase-
defective hDOT1L mutant suppressed continued cell e
Rgrowth of MLL-AF10- but not MLL-AFX-transformed
cells (Figure 3B). These results suggest that the enzy- Y
imatic activity of hDOT1L is not only required for trans-
formation but also required for maintaining the trans- 2
tformed status, raising the intriguing possibility that the
hDOT1L HMTase activity may serve as a target for ther- m
oapeutic intervention.
How does the enzymatic activity of hDOT1L contrib- s
Mute to leukemogenesis? Previous studies have demon-
strated a critical role in the upregulation of late Hoxa l
rgenes, particularly Hoxa9 and Hoxa7, in leukemogene-
sis mediated by MLL-ENL (Ayton and Cleary, 2003; q
(Kroon et al., 1998). Consistent with these observations,
direct fusion of hDOT1L to MLL resulted in upregulation a
aof a set of late Hoxa genes, including both Hoxa7 and
Hoxa9, similar to those upregulated by MLL-AF10 (Fig- l
fure 5A). Importantly, disruption of the Hoxa9 gene abro-
gated bone marrow transformation ability of MLL-AF10 Mr MLL-hDOT1L. ChIP assay demonstrated that bind-
ng of MLL-AF10/MLL-hDOT1L to the Hoxa9 gene in
ransformed cells correlates with hypermethylation of
3-K79 (Figure 6). Given that H3-K79 methylation has
een linked to transcriptional activation (Feng et al.,
002; Ng et al., 2002; van Leeuwen et al., 2002), hyper-
ethylation on H3-K79 probably contributes to Hoxa9
pregulation and leukemic transformation.
Recent studies have demonstrated that MLL is
leaved by Taspase-1 into two subunits, MLLN (p300)
nd MLLC (p180), which form a heterodimer (Hsieh et
l., 2003; Yokoyama et al., 2002). This cleavage is nec-
ssary for the expression of early Hoxa genes but is not
equired for the expression of late Hoxa genes, which
re overexpressed in many MLL-fusion leukemias
Hsieh et al., 2003). Several protein complexes contain-
ng the MLL heterodimer have been recently purified
Hughes et al., 2004; Nakamura et al., 2002; Yokoyama
t al., 2004). One complex contains MLL1/2, hAsh2,
bp5, WDR5, HCFs, and Menin (Hughes et al., 2004;
okoyama et al., 2004). The HCFs and Menin subunits
n this complex associate with MLLN (Yokoyama et al.,
004). Based on our studies and in consideration of
hese recent developments, we propose the following
odels, presented in Figure 7, to explain the functions
f MLL and its fusion proteins in normal and leukemia
tates. In normal myeloid differentiation (Figure 7A), the
LL complex uses its H3-K4 HMTase activity to estab-
ish H3-K4 methylation patterns on MLL target genes,
esulting in appropriate levels of gene expression re-
uired for normal myeloid differentiation. In leukemia
Figure 7B), however, fusion of MLL to its partners, such
s AF10, results in loss of the MLLC subcomplex as well
s the MLLN-associated HCFs, leading to decreased
evels of H3-K4 methylation. At the same time, protein
actors or enzymatic activities that associate with the
LL fusion partners are recruited to the MLL target
hDOT1L and Leukemia
177genes, leading to a different transcriptional outcome.
In the case of MLL-AF10, the associated factor is
hDOT1L, an H3-K79-specific HMTase. As a result, MLL
T
target genes become hypermethylated on H3-K79,
leading to their upregulation. This, in turn, may block
myeloid differentiation and promote proliferation, lead-
ing to leukemia. The HMTase-defective hDOT1L appa-
rently can function in a dominant-negative fashion by
competing for AF10 binding (Figure 7C). In this case,
methylation on both H3-K4 and H3-K79 of the MLL
target genes will be kept at a very low level, resulting
in very low or no expression of some MLL target genes.
Expression of some of these genes may be required for
cell proliferation or survival. As a result of the dominant-
negative effect, cells that express an hDOT1L mutant
may stop growing or undergo apoptosis.
In summary, our studies suggest that mistargeting of
hDOT1L and a subsequent change in the histone meth-
ylation pattern from H3-K4 to H3-K79 of key MLL target
genes, such as HoxA9, might be a crucial signal for
oncogenic transformation of myeloid cells in at least
some MLL-associated leukemias. The demonstration
that the enzymatic activity of hDOT1L is crucial for leu-
kemogenesis suggests that hDOT1L might be a poten-
tial target for therapeutic intervention. Thus, identifica-
tion of small molecules that are capable of disrupting
the interaction between hDOT1L and AF10 or inhibiting
the HMTase activity of hDOT1L might lead to a novel
treatment for leukemia. In this regard, our recent deter-
mination of the hDOT1L catalytic domain structure is of
particular relevance (Min et al., 2003a).
Experimental Procedures
Yeast Two-Hybrid Screen
To identify hDOT1L-interacting proteins, a yeast two-hybrid screen
was performed with the Matchmaker Gal4 two-hybrid system 3
(Clontech). The cDNA encoding the full-length hDOT1L was fused
in-frame to the GAL4 DNA binding domain in the bait vector-
pGBKT7. This construct was transformed into Saccharomyces
cerevisiae host strain AH109. A Pretransformed Mouse Testis
MATCHMAKER cDNA Library (Clontech) was screened following
instructions of the manufacturer. Approximately 4.8 × 106 individual
clones were screened and about 53 clones grew on the selected
medium lacking His, Ade, Trp, and Leu. The clones were further
selected by growth on SD/–Ade/–His/–Leu/–Trp/X-a-Gal master
plates. The prey plasmids were rescued and electroporated into
E. coli strain Top10. Of the 23 clones recovered, 18 encode the
C-terminal of AF10.
Constructs and Antibodies
For the mammalian two-hybrid assay (Clontech), various regions of
hDOT1L were cloned into the pM vector (Clontech) to generate fu-
sions with the Gal4 DNA binding domain. Various regions of AF10
were cloned into the pVP16 vector (Clontech) to generate fusions
with the VP16 transcriptional activation domain. pG5LUC is a re-
porter vector which contains the luciferase coding region down-
stream of the adenovirus E1b gene minimal promoter and five
GAL4 binding sites. For retroviral vector construction, the 5# LTR
region of murine stem cell virus vector (MSCVneo, Clontech) was
replaced by cytomegalovirus immediate early promoter sequences
(MSCN). MSCN-MLL(N) and MSCN-MLL-AF10 were constructed
from MSCV-5#MLL and MSCV-MLL-AF10 with a Flag tag upstream
of the MLL gene. MSCN-hDOT1L was constructed by inserting
hDOT1L cDNA (encoding amino acids 1–670) downstream of the
MLL gene. MSCB vector was constructed by replacement of the
neomycin-resistant gene of MSCN to the Blasticidin-resistant gene,
and the full-length hDOT1L with or without mutations in the SAMbinding site was inserted downstream of a Flag tag. RNAi con-
structs were made by synthesizing oligonucleotides encoding 21
bp short-hairpin RNA that target mDOT1L (RNAi1: 5#-GCACCATGA
GCTGCTCATGA-3#, RNAi2: 5#-GCTGGCCATGGAGAACTATGT-3#)
and cloned into pMSCV-derived Blasticidinr retrovirus vector under
the regulation of H1 RNA promoter. Antibodies against hDOT1L
were generated in rabbits using the first 391 amino acids as anti-
gen. The AF10 antibody was a gift from Dr. Bryan Young. Affinity-
purified antibodies against H3-2mK79 and H3-2mK4 have been
previously described (Feng et al., 2002).
Retrovirus Preparation, Transduction, and Colony Assays
Retroviral production and transduction of bone marrow progenitor
cells were essentially carried out as described (Coffield et al.,
2003). Briefly, MSCN or MSCB vectors containing MLL-AF10, MLL-
hDOT1L, etc. were cotransfected with pGag-pol and pVSVG to
293T cells by calcium-phosphate method. At 48 to 72 hr post-
transfection, the supernatants were collected and were used for
transduction of bone marrow progenitor cells prepared as follows:
4- to 12-week-old C57BL/6 mice or 6-month-old Hoxa9−/− mice
(provided by Dr. Michael Cleary) were injected intravenously with
5-fluorouracil (150 mg/kg), and bone marrow (BM) progenitor cells
were harvested from both femurs at 5 days postinjection. Retroviral
supernatants were used to transduce BM cells by spinoculation.
Two days after infection, infected cells were plated into methylcel-
lulose cultures.
For methylcellulose colony assays, 1 × 104 of retrovirally infected
BM progenitor cells were plated in 0.9% methylcellulose (Stem Cell
Technologies) supplemented with 10 ng/ml of murine IL-3, IL-6,
GM-CSF, 50 ng/ml SCF, and 3 g/ml hEpo in the presence of 1 mg/
ml G418 (GIBCO). After 7–10 days of culture, the number of colo-
nies was counted and the single-cell suspensions prepared from
G418-resistant colonies were replated into methylcellulose supple-
mented with the same growth factors without G418. Further plating
was repeated every 7–10 days. For the experiments in Figures 3A
and 3B, BM cells derived from a second round of plating were
plated on plates containing 5 g/ml of Blasticidin in the next day
of the infection of MSCB vectors. For the experiments in Figures
3C–3E, 5 g/ml of Blasticidin was used after the first infection, and
1 mg/ml of G418 was used after the second infection. For selection
of 3T3 cells (Figure S3), Blasticidin was applied with a final concen-
tration of 2 g/ml.
FACS Analysis
Cells harvested from the third round colonies of the methylcellulose
plating were incubated for 20 min on ice with CD16/CD32 Fc block
(BD Pharmingen, San Diego, California) and subsequently stained
for 30 min on ice with phycoerythrin-, fluorescein isothiocyanate-,
and allophycocyanin-conjugated isotype controls and monoclonal
antibodies against CD11b, Gr-1, c-kit, B220, CD3, IgE, and Ter119
(BD Pharmingen). Cells were then washed with 2% FBS-containing
PBS and analyzed using a FACSCalibur (BD Pharmingen), and col-
lected data were analyzed with Summit V3.1 (Cytomation Inc., Fort
Collins, Colorado).
Cell Culture, Transfections, Immunoprecipitation,
Immunofluorescent Staining, as well as Hox
Gene Expression and ChIP Assays
Please see Supplemental Data available with this article (see
below).
Supplemental Data
Supplemental Data include three figures and can be found with this
article online at http://www.cell.com/cgi/content/full/121/2/167/DC1/.
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